Leishmaniasis (Visceral - Leishmania spp.)
Overview
Plain-Language Overview
Visceral leishmaniasis is a serious infection caused by parasites called Leishmania species that primarily affect the body's internal organs, especially the liver, spleen, and bone marrow. This disease is transmitted through the bite of infected sandflies. It mainly impacts the immune system and blood cell production, leading to symptoms like fever, weight loss, and enlarged spleen and liver. The infection can cause severe anemia and increase the risk of other infections due to weakened immunity. Without treatment, it can be life-threatening because it disrupts the body's ability to fight infections and maintain healthy blood cells.
Clinical Definition
Visceral leishmaniasis is a systemic parasitic disease caused by the intracellular protozoa Leishmania donovani complex, transmitted by the bite of infected female sandflies. The core pathology involves the parasite's invasion and replication within macrophages of the reticuloendothelial system, primarily affecting the spleen, liver, and bone marrow. This leads to hepatosplenomegaly, pancytopenia, and hypergammaglobulinemia. The disease manifests with prolonged fever, weight loss, and immunosuppression, which predisposes to secondary infections. It is a major cause of morbidity and mortality in endemic regions, especially in tropical and subtropical areas. Diagnosis and management are critical due to the potential for fatal outcomes if untreated.
Inciting Event
Bite of infected female sandfly (genus Phlebotomus or Lutzomyia) transmits promastigote forms into human skin.
Inoculation of Leishmania promastigotes into the bloodstream initiates infection of macrophages.
Latency Period
Symptoms typically develop weeks to months after sandfly bite, with an incubation period of 2 to 6 months.
Latency can be prolonged in some cases, with clinical disease manifesting up to several months post-exposure.
Diagnostic Delay
Nonspecific symptoms such as fever, weight loss, and malaise often mimic other tropical infections, delaying diagnosis.
Lack of awareness and limited access to specific diagnostic tests in endemic areas contribute to delayed recognition.
Overlap with other causes of hepatosplenomegaly and pancytopenia leads to misdiagnosis.
Low sensitivity of early serologic tests and need for invasive tissue sampling can postpone definitive diagnosis.
Clinical Presentation
Signs & Symptoms
Fever is typically prolonged and intermittent, often with evening spikes.
Weight loss and fatigue result from chronic infection and systemic inflammation.
Night sweats are common due to immune activation.
Abdominal discomfort from organomegaly is frequently reported.
Anemia-related symptoms such as pallor and dyspnea on exertion occur due to marrow involvement.
History of Present Illness
Patients present with prolonged fever, weight loss, and fatigue progressing over weeks to months.
Development of painless hepatosplenomegaly is a hallmark feature.
History often includes recurrent infections due to immunosuppression and pancytopenia.
Night sweats and hyperpigmentation of the skin may be reported in advanced disease.
Past Medical History
Prior travel or residence in endemic regions is a critical historical clue.
History of immunosuppressive conditions such as HIV/AIDS or immunosuppressive therapy increases risk.
Previous episodes of cutaneous leishmaniasis may be present in some patients.
Family History
No significant heritable patterns or familial syndromes are associated with visceral leishmaniasis.
Family members may share exposure risk due to common environmental factors but not genetic predisposition.
Physical Exam Findings
Hepatosplenomegaly is a hallmark finding in visceral leishmaniasis due to parasite infiltration of the reticuloendothelial system.
Pancytopenia may be evident on peripheral exam due to bone marrow involvement.
Lymphadenopathy can be present but is less prominent than in other infections.
Cachexia and muscle wasting are common in advanced disease.
Pallor from anemia is frequently observed.
Diagnostic Workup
Diagnostic Criteria
Diagnosis is established by identifying amastigotes of Leishmania in tissue samples from the bone marrow, spleen, or lymph nodes using microscopy or culture. Serologic tests such as the rK39 antigen-based immunochromatographic test provide rapid and sensitive confirmation. PCR assays can detect parasite DNA with high specificity. Clinical features including prolonged fever, hepatosplenomegaly, and pancytopenia support the diagnosis but require parasitological or serological confirmation for definitive diagnosis.
Pathophysiology
Key Mechanisms
Infection by intracellular protozoa of the genus Leishmania leads to parasitization of macrophages and reticuloendothelial system cells.
Immune evasion occurs via inhibition of macrophage activation and suppression of cell-mediated immunity, allowing parasite survival and proliferation.
Dissemination of infected macrophages to the liver, spleen, and bone marrow causes organomegaly and hematologic abnormalities.
Chronic inflammation results in pancytopenia due to bone marrow infiltration and hypersplenism.
The cytokine response imbalance with inadequate Th1-mediated immunity contributes to disease progression and severity.
| Involvement | Details |
|---|---|
| Organs | Spleen undergoes massive enlargement due to hyperplasia of infected macrophages and immune cells, contributing to hypersplenism. |
Liver shows Kupffer cell hyperplasia and granulomatous inflammation as part of the host response to infection. | |
Bone marrow involvement leads to pancytopenia due to infiltration by infected macrophages and suppression of hematopoiesis. | |
| Tissues | Reticuloendothelial tissue including the spleen, liver, and bone marrow is heavily infiltrated by infected macrophages in visceral leishmaniasis. |
| Cells | Macrophages are the primary host cells infected by Leishmania spp. and serve as the site of parasite replication. |
T helper 1 (Th1) cells produce interferon-gamma to activate macrophages for intracellular parasite killing. | |
Dendritic cells present Leishmania antigens to T cells, initiating adaptive immune responses. | |
| Chemical Mediators | Interferon-gamma (IFN-γ) is critical for activating macrophages to kill intracellular Leishmania parasites. |
Tumor necrosis factor-alpha (TNF-α) promotes granuloma formation and parasite containment. | |
Interleukin-10 (IL-10) suppresses macrophage activation and can contribute to disease progression. |
Treatments
Pharmacological Treatments
Liposomal Amphotericin B
- Mechanism:
Binds to ergosterol in the parasite membrane causing increased membrane permeability and cell death
- Side effects:
Infusion reactions
Nephrotoxicity
Electrolyte imbalances
- Clinical role:
First-line
Pentavalent Antimonials (e.g., Sodium Stibogluconate)
- Mechanism:
Inhibits parasite glycolysis and fatty acid oxidation leading to parasite death
- Side effects:
Cardiotoxicity
Pancreatitis
Myalgia
- Clinical role:
Second-line
Miltefosine
- Mechanism:
Disrupts parasite membrane lipid metabolism and induces apoptosis
- Side effects:
Gastrointestinal upset
Teratogenicity
Elevated liver enzymes
- Clinical role:
Alternative first-line
Paromomycin
- Mechanism:
Inhibits protein synthesis by binding to the 30S ribosomal subunit of the parasite
- Side effects:
Nephrotoxicity
Ototoxicity
Injection site pain
- Clinical role:
Adjunctive
Non-pharmacological Treatments
Supportive care including nutritional support and management of anemia and secondary infections is essential in visceral leishmaniasis.
Vector control measures such as insecticide-treated nets and environmental sanitation reduce transmission risk.
Prevention
Pharmacological Prevention
No widely available chemoprophylaxis exists for visceral leishmaniasis.
Pentavalent antimonials and liposomal amphotericin B are used for treatment but not prevention.
Non-pharmacological Prevention
Vector control by reducing sandfly exposure through insecticide spraying and bed nets is essential.
Avoidance of sandfly habitats during peak activity times reduces transmission risk.
Use of protective clothing and insect repellents decreases sandfly bites.
Screening and treatment of infected individuals help reduce reservoir hosts.
Outcome & Complications
Complications
Secondary bacterial infections due to immunosuppression increase morbidity.
Severe anemia can lead to heart failure if untreated.
Bleeding diathesis from thrombocytopenia may cause hemorrhagic complications.
Post-kala-azar dermal leishmaniasis can develop after treatment.
Death may occur from untreated or complicated disease.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Leishmaniasis (Visceral - Leishmania spp.) versus Visceral Leishmaniasis vs. Malaria
Leishmaniasis (Visceral - Leishmania spp.) | Visceral Leishmaniasis vs. Malaria |
|---|---|
Exposure to sandfly bites in endemic areas of South Asia, East Africa, or South America | Recent travel to or residence in malaria-endemic regions with exposure to Anopheles mosquito bites |
Bone marrow or splenic aspirate showing intracellular amastigotes within macrophages | Peripheral blood smear showing intraerythrocytic ring forms or trophozoites |
Chronic fever with gradual onset, hepatosplenomegaly, and pancytopenia | Paroxysmal fevers with chills and rigors, often cyclical |
Leishmaniasis (Visceral - Leishmania spp.) versus Visceral Leishmaniasis vs. Chronic Myelogenous Leukemia (CML)
Leishmaniasis (Visceral - Leishmania spp.) | Visceral Leishmaniasis vs. Chronic Myelogenous Leukemia (CML) |
|---|---|
Pancytopenia with prominent anemia and thrombocytopenia | Marked leukocytosis with left shift and basophilia |
Identification of Leishmania amastigotes on tissue biopsy or aspirate | Presence of BCR-ABL fusion gene by PCR or FISH |
Protozoan parasite within macrophages | Neoplastic myeloid proliferation without infectious organisms |
Leishmaniasis (Visceral - Leishmania spp.) versus Visceral Leishmaniasis vs. Tuberculosis (Disseminated)
Leishmaniasis (Visceral - Leishmania spp.) | Visceral Leishmaniasis vs. Tuberculosis (Disseminated) |
|---|---|
Exposure to sandfly vector in endemic regions | History of exposure to individuals with active pulmonary tuberculosis or residence in high TB prevalence areas |
Imaging showing hepatosplenomegaly without primary lung involvement | Chest imaging showing pulmonary infiltrates, cavitations, or miliary pattern |
Visualization of Leishmania amastigotes in tissue aspirates | Positive acid-fast bacilli stain or culture from tissue or sputum |
Leishmaniasis (Visceral - Leishmania spp.) versus Visceral Leishmaniasis vs. Kala-azar Relapse or Post-Kala-azar Dermal Leishmaniasis
Leishmaniasis (Visceral - Leishmania spp.) | Visceral Leishmaniasis vs. Kala-azar Relapse or Post-Kala-azar Dermal Leishmaniasis |
|---|---|
Systemic symptoms with fever, hepatosplenomegaly, and pancytopenia during active visceral infection | Cutaneous nodules or hypopigmented macules developing after initial visceral disease treatment |
Parasites predominantly within reticuloendothelial system macrophages | Leishmania parasites localized to dermis with granulomatous inflammation |
Leishmaniasis (Visceral - Leishmania spp.) versus Visceral Leishmaniasis vs. HIV-associated Opportunistic Infections
Leishmaniasis (Visceral - Leishmania spp.) | Visceral Leishmaniasis vs. HIV-associated Opportunistic Infections |
|---|---|
Immunocompetent or mildly immunosuppressed host with Leishmania infection | Severe CD4+ T cell depletion with opportunistic infections like Mycobacterium avium complex or Cryptococcus |
Detection of Leishmania amastigotes in tissue aspirates or PCR | Identification of specific opportunistic pathogens by culture or antigen testing |